RCMI Coordinating Center (RCMI CC) Header Logo

Connection

David A. Foster to Glutamine

This is a "connection" page, showing publications David A. Foster has written about Glutamine.
Connection Strength

2.424
  1. Hatipoglu A, Menon D, Levy T, Frias MA, Foster DA. Inhibiting glutamine utilization creates a synthetic lethality for suppression of ATP citrate lyase in KRas-driven cancer cells. PLoS One. 2022; 17(10):e0276579.
    View in: PubMed
    Score: 0.852
  2. Bernfeld E, Foster DA. Glutamine as an Essential Amino Acid for KRas-Driven Cancer Cells. Trends Endocrinol Metab. 2019 06; 30(6):357-368.
    View in: PubMed
    Score: 0.669
  3. Bernfeld E, Menon D, Vaghela V, Zerin I, Faruque P, Frias MA, Foster DA. Phospholipase D-dependent mTOR complex 1 (mTORC1) activation by glutamine. J Biol Chem. 2018 10 19; 293(42):16390-16401.
    View in: PubMed
    Score: 0.641
  4. Patel D, Salloum D, Saqcena M, Chatterjee A, Mroz V, Ohh M, Foster DA. A Late G1 Lipid Checkpoint That Is Dysregulated in Clear Cell Renal Carcinoma Cells. J Biol Chem. 2017 01 20; 292(3):936-944.
    View in: PubMed
    Score: 0.142
  5. Foster DA, Salloum D, Menon D, Frias MA. Phospholipase D and the maintenance of phosphatidic acid levels for regulation of mammalian target of rapamycin (mTOR). J Biol Chem. 2014 Aug 15; 289(33):22583-22588.
    View in: PubMed
    Score: 0.120
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support